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ABSTRACT OF THESIS 
 
 
RELATIONSHIP BETWEEN INITIAL PRESCRIPTION OPIOID EXPOSURE 
LENGTH AND FUTURE OPIOID USE DISORDER DIAGNOSIS 
 IN OPIOID NAÏVE ADOLESCENTS 
 
 Objectives: The long-term risks associated with the use of short-term prescription 
opioids in opioid naïve adolescents in not well characterized. The purpose of this study 
was to explore the potential association between the days’ supply of the initial 
prescription opioid exposure and the rates of diagnosed OUD in the subsequent 3-year 
period. Methods: We conducted a retrospective cohort study using a nationwide database 
of commercially-insured adolescents aged 12-17 at the time of the index opioid fill. A 
multivariable Cox Proportional Hazard regression model was developed to analyze the 
association of interest while accounting for known risk factors for the development of 
OUD. Results: Results of the Cox Proportional Hazard analysis showed no significant 
differences in the risks of future OUD diagnosis between any of the days’ supply groups. 
Conclusions: In this commercially-insured, opioid naïve adolescent population, there was 
no significant association between the days’ supply of the initial opioid prescription the 
rate of OUD diagnosis in the subsequent 3-year period.  
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CHAPTER 1.  INTRODUCTION 
As the opioid crisis continues to grip the nation, there remains a need to better 
understand the risks of opioid use and the pathways that lead to opioid use disorder (OUD). 
OUD, previously classified as ‘opioid abuse’ or ‘opioid dependence’, is a mental disorder 
included in the most recent Diagnostic and Statistical Manual of Mental Disorders (DSM-
5).1 It is defined by the American Psychiatric Association as ‘a problematic pattern of 
opioid use that causes significant impairment or distress’.2  Diagnosis is based on an 11 
point questionnaire about characteristics of opioid use, lifestyle impact, and indicators of 
opioid tolerance and withdrawal.1 The presence of two indicators qualifies a patient for a 
OUD diagnosis, with ‘mild’ severity. ‘Moderate’ and ‘severe’ OUD diagnoses occur with 
the presence of four and six indicators respectively.3 OUD affects a significant number of 
people in the United States, as well as the rest of the world. According to the U.S. Centers 
for Disease Control and Prevention (CDC), an estimated 2.1 million Americans had OUD 
in 2016.2 An OUD diagnosis is associated with an increase in the rates of patient morbidity 
and mortality. Patients with OUD have higher rates of acute hospitalization, emergency 
department visits, and opioid related complications, as well as increased healthcare costs.4,5  
The risk of death is also significantly increased, with mortality rates up to 20 times higher 
than that of the general population.6 Furthermore, patients with OUD who use opioids 
intravenously place themselves at increased risk for serious comorbidities such as bacterial 
endocarditis, HIV, and hepatitis.4   
It has been found that many patients with OUD had their initial exposure to opioids 
through opioids prescribed to them by a medical professional, often for acute pain.7,8 As 
the risks of prescription opioid use became better understood, there were increased efforts 
to develop guidelines aimed at reducing opioid prescribing. This focus has led to reductions 
in the amount of prescription opioids dispensed. Since 2011, there has been an estimated 
43% decrease in opioid analgesic prescription volume, in morphine milligram equivalents 
(MME). However, these medications continue to be widely prescribed and their use 
remains well above pre-2000 levels.9,10  The CDC estimates there were 58 opioid 
prescriptions written per 100 Americans in 2017, with 46 people dying every day from 
prescription opioid-related overdoses.11,12 Additionally, the IQVIA Institute estimates that 
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acetaminophen/hydrocodone combination medications were the fifth most dispensed class 
of medications the US in 2018.10 These statistics indicate that opioid use in the United 
States is still high, and reiterate the importance of finding ways to reduce the incidence of 
OUD and opioid-related harm. 
Many patient characteristics have been shown to predispose a patient to developing 
OUD.  A history of a substance use disorder (SUD) and certain mental health diagnoses, 
such as psychotic disorders, personality disorders and anxiety disorders, are associated with 
an increased risk of developing OUD.6,13 Additionally, indicators of economic 
disadvantage have also been associated with the development of OUD, including a lack of 
insurance, unemployment, and income.14 Furthermore, male gender, Caucasian ethnicity, 
age at first opioid exposure, single marital status, and poor self-reported health have also 
been associated with OUD.13,15–18 Genetics may also play a role in predisposition to OUD, 
however this is less well understood.19 
It is also important to understand the characteristics of the initial opioid exposure that 
are associated with OUD, and possible indicators of OUD such as the transition from acute 
to chronic use. Since many patients with OUD were initially exposed to opioids through a 
legitimate prescription, these correlations are important in developing clinical guidelines 
and best practices.20 Various prescription characteristics have been associated with long 
term opioid use and OUD, including higher daily opioid dose (in Morphine Milligram 
Equivalents; MME), the use of long acting or extended release opioids, refill count, and 
increasing days’ supply of the initial prescription.13,20–24 Interestingly, multiple 
retrospective studies have found that the length of the initial opioid prescription was a more 
important factor than opioid dose when predicting the risk of future OUD.8,21,25 Guidelines 
from the CDC suggest that treatment durations of 3 days or less will often be sufficient to 
treat acute pain, with treatment durations of 7 days or more rarely being necessary.20,26  
Other research suggests that the risks of transitioning from acute to chronic opioid use 
begin to increase starting with the third day of opioid therapy, and rise sharply after the 
fifth and thirty first days of therapy.27 
While an increasing duration of the initial opioid prescription may increase the risk of 
developing OUD, shorter prescriptions may still pose significant risk. It is known that 
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prolonged opioid exposure puts patients at risk for OUD due to the risks of physical 
dependence, which increase sharply after 5 days of exposure.20 However, initial opioid 
exposures of less than 5 days may also place patients at risk of future OUD, but for a 
different reason. Regardless of the length of the initial exposure, the prescribed opioid may 
be a patient’s first experience with a mind-altering drug. The pleasurable feelings 
associated with opioids may cause patients to seek out these drugs, despite a lack of 
physical dependence.  It has been found that adolescents with little to no prior experience 
with illicit drugs are at an increased risk for future opioid misuse, when compared to their 
peers with prior exposure.28 This seems to support the idea that the mind-altering effects 
of the opioid may be more profound in those with no prior exposure to mind altering drugs. 
It has also been found that the risks of future opioid misuse may be higher in adolescents 
who, at baseline, strongly disapprove of illegal drug use.28  While these patients may avoid 
exposure to opioids via illicit means, this barrier to is removed when the initial exposure is 
via a legitimate prescription.  This widens the spectrum of at-risk patients to include those 
who would not otherwise have been exposed to opioids. This data provides evidence for 
the claim that all lengths of initial exposures may be dangerous, but the reasoning for the 
transition to OUD may differ based on the length of the initial exposure.  
Adolescents (aged 12-17) are a subset of the population that is often exposed to opioids 
as well. Adolescents commonly experience procedures in which opioids are commonly 
prescribed, such as dental work, surgery, and sports injuries, which may place them at 
higher risk for opioid related problems in the future.29–33 By high school graduation, an 
estimated 25% of adolescents have been exposed to prescription opioids through either 
medical or nonmedical means.34 No other illicit substance is abused more prevalently in 
the 12-17 age group, aside from marijuana.35 While adolescents share many of the same 
OUD risk factors with adults, factors such as prior exposure to illicit substances, 
motivations for opioid use, social pressures, and neurologic development may differ 
between the two groups. Therefore, it is important to study these populations separately. 
As mentioned previously, a lack of prior exposure to mind altering substances may 
predispose patients to future OUD, even after a single opioid exposure. This risk may 
disproportionately affect adolescents, as they are less likely to have prior experience with 
illicit substances or alcohol. Another difference between adults and adolescents are the 
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varying motivations for using opioids nonmedically. One survey based study found that 
adults were 42% more likely than adolescents to report abusing opioids in an attempt to 
relieve physical pain.14  In contrast, another survey based study found that high school 
seniors were more likely to report using opioids nonmedically to ‘relax’ or ‘get high.’36 
Additionally, the decision-making systems of the adolescent brain are less developed than 
those in adults.  While the areas of the brain that handle feelings of reward and pain are 
well developed by the time of adolescence, the areas involved in decision-making and 
judgement are not fully developed until the mid-twenties.37 Since the reward system of the 
adolescent brain is intimately involved in drug use, this differentiates them from adults.  
These factors, coupled with the extensive peer pressure and desire to fit in, could affect the 
transition from opioid use to OUD in adolescents.37  
Both governmental and non-governmental bodies have recognized the potential link 
between days’ supply and the risks of chronic opioid use and future OUD and have worked 
to place limits on the length of initial opioid prescriptions. Since 2016 when the first 
legislation was passed in Massachusetts, at least 33 states have adopted some type of opioid 
prescription limitations.38 The legislation varies in the method used to restrict initial opioid 
prescriptions.  Methods include limiting the days’ supply, limiting the maximum opioid 
dose (MME), and directing other entities to develop these limitations (such as a state health 
organization or provider regulatory board). Most commonly, legislation creates statutory 
limits on the maximum days’ supply of the initial opioid prescription. These limits vary 
between 3 and 14 days, with the most common days’ supply limit being 7 days.38 Non-
governmental organizations have also implemented policies to restrict the days’ supply of 
the initial opioid fill, with both CVS and Walmart restricting the filling of initial acute 
opioid prescriptions to a 7 day supply.39,40 Despite these limitations, there are often 
exceptions to these rules, such as the treatment of chronic pain, cancer, or palliative care.38 
Additionally, these restrictions can often be overruled based on the professional judgement 
of the provider, often requiring explicit documentation of the exception in the patient’s 
medical record. Some states have also taken steps to further limit access to opioids by 
adolescents, and have developed limits specifically for this population.38 These laws may 
extend limits on opioid prescriptions beyond the initial fill, or include other requirements 
such as mandatory counseling of the minor and/or guardian on the risks of opioid use.  
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Due to the relatively new implementation of these laws, it is too early to tell which 
days’ supply limit, if any, will lead to reductions in OUD. It is also unclear which days’ 
supply, if any, increases an adolescent’s risk for developing OUD. As more states move to 
implement these laws, further research into the effect of days’ supply on the risks of future 
OUD can help inform policymakers on overall effective approaches and whether or not the 
adolescent population should be treated differently than adults when considering such 
legislation.   
While there is research describing potential factors influencing the risks of future OUD 
in adolescents, the effect of days’ supply is less well understood.  The majority of studies 
looking at this age group utilize self-reported questionnaires or geographically 
homogenous populations.  Furthermore, relevant studies that do utilize claims data to study 
long term opioid misuse do not focus specifically on the adolescent population. Further 
analysis of this topic using nationwide claims data may help better inform 
recommendations on limiting the length of OUD prescriptions in adolescents.  The main 
objective of this study is to determine if there is an association between the days’ supply 
of the index opioid fill and the rate of future OUD diagnosis in adolescents. We hypothesize 
that the rates of diagnosed OUD will begin to significantly increase in patients receiving 
an index opioid prescription of longer than 7 days. Secondary objectives for this study are 
to determine the prevalence of OUD diagnosis in the population, the average MME per day 
of the index prescription, and the average days’ supply of the initial prescription. These 





CHAPTER 2. METHODS 
2.1 Data Source 
This study used deidentified health claims from a large commercially insured 
population of about 23 million patients for the period of 2008-2017.  Patients are 
demographically representative of the US population with respect to gender and age, and 
representative of the commercially-insured population on all other measurable 
characteristics. 
2.2 Study Population 
All patients with the following characteristics were included in the analysis: (1) at 
least one opioid prescription between January 1st 2008 and December 31st 2017 as 
identified using Generic Product Identifier (GPI) codes beginning with ‘65’ (2) at least 6 
months of continuous enrollment without an opioid prescription before the index fill, and 
(3) between the ages of 12 and 17 at the time of the index opioid prescription. Patients with 
the following characteristics were excluded from the analysis: (1) patients whose first 
prescription was for a buprenorphine product, (2) patients with a cancer diagnosis in the 6 
month lookback period, (3) patients whose first opioid fill was for a Schedule V opioid, (4) 
patients with a diagnosis of OUD prior to their first opioid fill, (5) patients with an initial 
opioid prescription days’ supply of more than 14 days, and (6) patients whose demographic 
information was incomplete or invalid. Patients whose index opioid fill was for a 
buprenorphine product were excluded from the analysis as buprenorphine containing 
medications are often used in the treatment of OUD. While buprenorphine containing 
products have demonstrated some efficacy in the treatment of pain, their use is widely 
popular in medication assisted treatment (MAT) for OUD.41  To avoid the possibility of 
the results being affected by missing or incorrectly coded OUD diagnoses, these patients 
were excluded from the analysis. Consistent with other studies, patients with a cancer 
diagnosis in the 6-month lookback period were also excluded. Patients whose index opioid 
fill was for a Schedule V opioid were excluded from the analysis as this class of opioids, 
which includes medications such as atropine-diphenoxylate and low potency codeine-
containing cough syrups, are typically used to treat conditions other than pain. Finally, 
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since the focus of this study is the effects of acute opioid exposure, patients with initial 
prescriptions of longer than 14 days were excluded.  
2.3 Outcome 
 Patients were followed from the date of their first opioid prescription until 
insurance disenrollment, OUD diagnosis, 3 years of continuous follow up, or the end of 
the dataset period, whichever came first (Figure 2.1). Consistent with previous studies, 
OUD was defined as a patient with any ICD-9 or ICD-10 diagnosis code for opioid 
dependence or opioid abuse in any diagnosis field of the claim (Appendix A).8 
 Using the days’ supply of the first prescription opioid fill, patients were divided 
into categories based on common days’ supply limitations enacted by states (1-3 days, 3-4 
days, 5-7 days, and 8-14 days). MME per day was calculated by multiplying the daily dose 
(in milligrams) of the prescription by the MME conversion factor. Conversion factors were 
gathered from the Centers for Medicare and Medicaid Services (CMS).42 A conversion 
factor for propoxyphene-containing products was not included in the resource from CMS, 
and was gathered from another source.43 90 MME per day was chosen as the cutoff for a 
‘high dose’ opioid, to create a binary variable for inclusion into the statistical model. This 
threshold was chosen based on the CDC’s recommendation that dosages over 90 MME/day 
should be avoided, as they can increase the risk of an opioid overdose death by a factor of 
ten.7,44 To account for patients with comorbid psychiatric conditions that could predispose 
them to OUD, a binary variable was created for the presence of these conditions. A search 
was performed for psychotic, anxiety, and personality disorders using ICD-9 and ICD-10 
diagnosis (Appendix B). If the patient was found to have a diagnosis code for any of these 
conditions during the study period, they were included in the psychiatric subgroup.  
2.4 Statistical Analysis 
A multivariable Cox-proportional hazard regression model was developed to 
determine the association between the days’ supply of the index opioid prescription on the 
likelihood of an OUD diagnosis in the subsequent 3 year (1,095 days) follow up period. 
Covariates for the days’ supply group, age at index opioid fill, gender, race, MME per day, 
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socioeconomic status, and presence of comorbid psychiatric disorders were included in the 
model. These covariates were chosen due to their previously described association with 
OUD. All analyses were conducted using SAS version 9.4 (SAS Institute, Cary NC). Since 











CHAPTER 3. RESULTS 
3.1 Demographics 
After applying inclusion and exclusion criteria, 284,514 patients who met study 
criteria were identified (Figure 3.1). Table 3.1 provides a summary of patient 
demographics. Patients were an average of 15.3 (1.58) years of age and similarly divided 
by gender. Patients in the 16-17 age group accounted for 156,723 (55.1%) of opioid 
prescriptions.  The vast majority (79.6%) were white and 13.4% had a psychiatric disorder 
diagnosis. Table 3.2 summarizes the characteristics of index opioid prescriptions.  The two 
most common opioids found in the index prescriptions were hydrocodone and codeine 
containing products, which accounted for 174,484 (61.3%) and 51,337 (18.0%) of 
prescriptions, respectively. Prescriptions of 3 days were the most common in the study 
population, accounting for 79,459 (27.9%) of prescriptions. After assignment into groups 
based on the days’ supply of the initial prescription, the most common category was 1-3 
days, which accounted for 180,326 (63.4%) patients. The least common category was 8-14 
days, which accounted for only 20,647 (7.3%) of prescriptions. The average daily dose of 
the index opioid fills was 37.1 ( 21.8) MME with few (3.5%) dispensed that were over 90 
MME daily. Overall, during the 3 year follow up period, OUD was diagnosed in 423 
(0.15%) patients in the study population.  Among patients who were diagnosed with OUD 
within 3 years of their index opioid fill, the mean time to diagnosis was 473 days (~1.3 
years). 
3.2 Statistical Analysis 
Results of the Cox Proportional Hazard analysis (Table 3.3) showed no significant 
differences in the risks of future OUD diagnosis between any of the days’ supply groups. 
As expected, male gender, increasing age, and the presence of psychiatric disorder 
diagnoses were associated with increased risk of an OUD diagnosis within 3 years of the 
index opioid fill. No significant differences in the risk of future OUD diagnosis was seen 
among race, year of index opioid fill, indicators of income, or whether or not the daily 
MME was considered ‘high dose’. Survival curves were generated for overall survival 
(Figure 3.2) and survival stratified by days’ supply group (Figure 3.3).  
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Table 3.1: Patient Demographics (n=284,514) 
Characteristic 
Overall 1-3 Days 4-5 Days 6-7 Days 8-14 Days 
Value (%) Value (%) Value (%) Value (%) Value (%) 
Patient Count 284,514 180,326 (63.4) 59,255 (20.8) 24,286 (8.5) 20,647 (7.3) 
Gender 
Male 144,216 (50.7) 90,214 (62.6) 30,741 (21.3) 12,582 (8.7) 10,679 (7.4) 
Female 140,298 (49.3) 90,112 (64.2) 28,514 (20.3) 11,704 (8.3) 9,968 (7.1) 
Race 
White 226,481 (79.6) 144,713 (63.9) 46,758 (20.7) 18,880 (8.3) 16,130 (7.1) 
Hispanic 26,373 (9.3) 15,986 (60.6) 5,810 (22.0) 2,469 (9.4) 2,108 (8.0) 
Black 23,322 (8.2) 14,265 (61.2) 4,975 (21.3) 2,190 (9.4) 1,892 (8.1) 
Asian 8,338 (2.9) 5,362 (64.3) 1,712 (20.5) 747 (9.0) 517 (6.2) 
Household Income 
> 400% Poverty Line 282,695 (99.4) 179,191 (63.4) 58,866 (20.8) 24,123 (8.5) 20,515 (7.3) 
< 400% Poverty Line 1,819 (0.6) 1,135 (62.4) 389 (21.4) 163 (9.0) 132 (7.3) 
Psychiatric Disorder Diagnosis 
No 246,428 (86.6) 155,866 (63.3) 51,620 (21.0) 21,098 (8.6) 17,844 (7.2) 
Yes 38,086 (13.4) 24,460 (64.2) 7,635 (20.1) 3,188 (8.4) 2,803 (7.4) 
OUD Diagnosis During Study 
Yes 423 (0.15) 282 (66.7) 80 (18.9) 30 (7.1) 31 (7.3) 





Table 3.2: Index Opioid Fill Characteristics (n=284,514) 
Characteristic Value Percent (%) 
Days’ Supply 
1-3 days 180,326 63.4 
4-5 days 59,255 20.8 
6-7 days 24,286 8.5 
8-14 days 20,647 7.3 
Daily MME 
< 90 274,580 96.5 
90+ 9,917 3.5 
Most Prevalent Opioids 
Hydrocodone/Acetaminophen 171,530 60.3 
Codeine/Acetaminophen 51,103 18.0 
Oxycodone/Acetaminophen 36,322 12.8 
Tramadol HCl 8,505 3.0 





Table 3.3: Cox-proportional Hazard Regression Model Results (n=284,514) 
Characteristic Hazard Ratio 95% CI 
Days’ Supply Group 
1-3 Ref - 
4-5 0.959 0.710 – 1.208 
6-7 0.923 0.546 – 1.300 
8-14 1.234 0.862 – 1.606 
Daily MME 
< 90 MME Ref - 
90+ MME 0.825 0.290 – 1.360 
Gender 
Female Ref - 
Male 2.15a 1.950 – 2.350 
Age Group 
12-13 Ref - 
14-15 3.315a 2.782 – 3.848 
16-17 5.572a 5.249 – 6.255 
Race 
White Ref - 
Asian 0.569 -0.239 – 1.377 
Black 0.875 0.483 – 1.267 
Hispanic 0.661 0.255 – 1.067 
Household Income 
> 400% Poverty Line Ref - 
< 400% Poverty Line 1.376 0.238 – 2.514 
Psychiatric Disorder Diagnosis 
No Ref - 
Yes 10.635a 10.434 – 10.836 





















CHAPTER 4. DISCUSSION 
4.1 Discussion of Results 
In this study of 284,414 privately insured, opioid naïve U.S. adolescents, no 
association was found between the days’ supply of the index opioid prescription and the 
risk of OUD diagnosis in the subsequent 3-year period. Even for prescriptions of less than 
3 days, thought to be too short to cause physical dependence, the risk of future OUD 
diagnosis is not significantly lower than prescriptions of 8-14 days. While no other study 
has found an association between days’ supply and future OUD diagnosis in adolescents, 
other studies have found links between days’ supply and surrogates of OUD, such as opioid 
overdose and a transition to long term opioid use. One study of 1.3 million privately insured 
patients 14 years and older found that the probability of continued opioid use increases 
steadily with the days’ supply of the initial opioid fill, with days’ supplies up to >22 days. 
The study found that, when compared to initial prescriptions of 2 days or less, prescriptions 
of 5-7 days and 8-10 days increased the chances of long term opioid use by a factor of three 
and a factor of five, respectively. 8 A second study found a substantial increase in the 
probability of continued opioid use in opioid naïve adults once the days’ supply of the 
initial prescription reached 6 days, with another substantial increase after 10 days.27 A third 
study looking at post-surgical opioid naïve adults found that each additional week of opioid 
supply increased the risk of future opioid misuse by 20%.45  
While this finding does not give specific guidance on days’ supply limits to states 
considering statutory limitations on initial opioid prescriptions, these findings may support 
the consideration of differing limitations on adolescents compared to adults. While other 
studies in adults show that the risk of OUD diagnoses may increase with days’ supply, this 
data does not support that in adolescents.  Rather, it shows that a shorter days’ supply is no 
‘safer’ than a longer days’ supply in adolescents. While all medications should be 
prescribed for the lowest possible dose for the shortest duration, prescribers should remain 
especially cognizant of this for opioids given the state of the opioid epidemic.   
Consistent with previous literature, the results also showed that male gender, 
increased age at exposure, and comorbid psychiatric disorders were associated with an 
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increased incidence of OUD. In contrast to previous studies, no increase in the incidence 
of OUD diagnosis was seen in regard to race or indicators of socioeconomic status. High 
dose opioids (90+ MME) were also not found to increase the risk of a future OUD 
diagnosis. The findings of OUD diagnosis rates (0.15%) and time to OUD diagnosis (~1.3 
years) in this study were lower when compared to a prior study of opioid naïve patients in 
the post-surgical setting. The study included 146,556 patients age 24 and under, in which 
opioid misuse was subsequently identified in 0.22% of patients <15 years of age, and 
1.25% in patients aged 15-24. The mean time to opioid misuse was 2.39 years in patients 
<15 years old, and 1.47 years in patients 15-24.45  
4.2 Limitations 
Several limitations must be considered when interpreting these results. First, no 
control group containing patients without an opioid exposure was included in this study. 
Due to the difficulty in accounting for the multitude of risk factors that may vary between 
opioid users and non-opioid users, this element was not pursued in this analysis. The 
absence of this control group means the baseline rate of OUD diagnosis is unable to be 
determined in this cohort. Secondly, this dataset only included commercially insured 
patients. Therefore, uninsured patients and patients covered under Medicaid were not 
included in this analysis, leaving out a large proportion of opioid users with many risk 
factors for OUD.  Additionally, this study relies on medical coding for OUD diagnosis 
information and comorbid condition identification, both during the study period and the 
six-month lookback period. Errors or omissions common with medical coding could affect 
the results.  Due to the nature of claims data, it is impossible to determine if the medications 
were taken as directed, or even taken at all. Also, prescriptions not run through insurance 
would not be captured in this dataset. Additionally, this study did not consider 
characteristics of opioid exposures other than the index fill. This could lead to inter-patient 
variability in subsequent opioid exposures, which could affect the risks of OUD diagnosis. 
Also, while this study incorporated a six-month lookback period, a patient may have been 
exposed to opioids prior to this lookback period, meaning the patient would not truly be 
opioid naïve.  Pain etiology and a patient’s history of other substance use disorders were 
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also not included in this analysis, and this information has been shown to affect the risks 
of OUD.   
4.3 Conclusions 
 In this commercially-insured, opioid naïve adolescent population, there was no 
significant association between the days’ supply of the initial opioid prescription the rate 
of OUD diagnosis in the subsequent 3-year period. This data suggests that the risk of 
future OUD for initial opioid exposures of 1-3 days, thought to be too short to induce 
physical dependence, are not significantly different than prescriptions lengths of up to 14 
days.  Extra caution should be taken when prescribing opioids of any duration, especially 





Appendix A: Diagnosis Codes for Opioid Use Disorder  
304.00 Opioid type dependence, unspecified 
304.01 Opioid type dependence, continuous 
304.02 Opioid type dependence, episodic 
304.03 Opioid type dependence, in remission 
304.70 Combinations of opioid type drug with any other drug dependence, unspecified 
304.71 Combinations of opioid type drug with any other drug dependence, continuous 
304.72 Combinations of opioid type drug with any other drug dependence, episodic 
304.73 Combinations of opioid type drug with any other drug dependence, in remission 
305.50 Opioid abuse, unspecified 
305.51 Opioid abuse, continuous 
305.52 Opioid abuse, episodic 
305.53 Opioid abuse, in remission 
F11.10 Opioid abuse, uncomplicated 
F11.120 Opioid abuse with intoxication, uncomplicated 
F11.121 Opioid abuse with intoxication delirium 
F11.122 Opioid abuse with intoxication with perceptual disturbance 
F11.129 Opioid abuse with intoxication, unspecified 
F11.14 Opioid abuse with opioid-induced mood disorder 
F11.150 Opioid abuse with opioid-induced psychotic disorder with delusions 
F11.151 Opioid abuse with opioid-induced psychotic disorder with hallucinations 
F11.159 Opioid abuse with opioid-induced psychotic disorder, unspecified 
F11.181 Opioid abuse with opioid-induced sexual dysfunction 
F11.182 Opioid abuse with opioid-induced sleep disorder 
F11.188 Opioid abuse with other opioid-induced disorder 
F11.19 Opioid abuse with unspecified opioid-induced disorder 
F11.20 Opioid dependence, uncomplicated 
F11.21 Opioid dependence, in remission 
F11.220 Opioid dependence with intoxication, uncomplicated 
F11.221 Opioid dependence with intoxication delirium 
F11.222 Opioid dependence with intoxication with perceptual disturbance 
F11.229 Opioid dependence with intoxication, unspecified 
F11.23 Opioid dependence with withdrawal 
F11.24 Opioid dependence with opioid-induced mood disorder 
F11.250 Opioid dependence with opioid-induced psychotic disorder with delusions 
F11.251 Opioid dependence with opioid-induced psychotic disorder with hallucinations 
F11.259 Opioid dependence with opioid-induced psychotic disorder, unspecified 
F11.281 Opioid dependence with opioid-induced sexual dysfunction 
F11.282 Opioid dependence with opioid-induced sleep disorder 
F11.288 Opioid dependence with other opioid-induced disorder 
F11.29 Opioid dependence with unspecified opioid-induced disorder 
F11.90 Opioid use, unspecified, uncomplicated 
F11.920 Opioid use, unspecified with intoxication, uncomplicated 
F11.921 Opioid use, unspecified with intoxication delirium 
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F11.922 Opioid use, unspecified with intoxication with perceptual disturbance 
F11.929 Opioid use, unspecified with intoxication, unspecified 
F11.93 Opioid use, unspecified with withdrawal 
F11.94 Opioid use, unspecified with opioid-induced mood disorder 
F11.950 Opioid use, unspecified with opioid-induced psychotic disorder with delusions 
F11.951 Opioid use, unspecified with opioid-induced psychotic disorder with hallucinations 
F11.959 Opioid use, unspecified with opioid-induced psychotic disorder, unspecified 
F11.981 Opioid use, unspecified with opioid-induced sexual dysfunction 
F11.982 Opioid use, unspecified with opioid-induced sleep disorder 
F11.988 Opioid use, unspecified with other opioid-induced disorder 





Appendix B: Diagnosis Codes for Psychiatric Disorders 
Psychotic Disorders 
295.00 Simple type schizophrenia, unspecified 
295.01 Simple type schizophrenia, subchronic 
295.02 Simple type schizophrenia, chronic 
295.03 Simple type schizophrenia, subchronic with acute exacerbation 
295.04 Simple type schizophrenia, chronic with acute exacerbation 
295.05 Simple type schizophrenia, in remission 
295.10 Disorganized type schizophrenia, unspecified 
295.11 Disorganized type schizophrenia, subchronic 
295.12 Disorganized type schizophrenia, chronic 
295.13 Disorganized type schizophrenia, subchronic with acute exacerbation 
295.14 Disorganized type schizophrenia, chronic with acute exacerbation 
295.15 Disorganized type schizophrenia, in remission 
295.20 Catatonic type schizophrenia, unspecified 
295.21 Catatonic type schizophrenia, subchronic 
295.22 Catatonic type schizophrenia, chronic 
295.23 Catatonic type schizophrenia, subchronic with acute exacerbation 
295.24 Catatonic type schizophrenia, chronic with acute exacerbation 
295.25 Catatonic type schizophrenia, in remission 
295.30 Paranoid type schizophrenia, unspecified 
295.31 Paranoid type schizophrenia, subchronic 
295.32 Paranoid type schizophrenia, chronic 
295.33 Paranoid type schizophrenia, subchronic with acute exacerbation 
295.34 Paranoid type schizophrenia, chronic with acute exacerbation 
295.35 Paranoid type schizophrenia, in remission 
295.40 Schizophreniform disorder, unspecified 
295.41 Schizophreniform disorder, subchronic  
295.42 Schizophreniform disorder, chronic 
295.43 Schizophreniform disorder, subchronic with acute exacerbation 
295.44 Schizophreniform disorder, chronic with acute exacerbation 
295.45 Schizophreniform disorder, in remission 
295.50 Latent schizophrenia, unspecified 
295.51 Latent schizophrenia, subchronic 
295.52 Latent schizophrenia, chronic 
295.53 Latent schizophrenia, subchronic with acute exacerbation 
295.54 Latent schizophrenia, chronic with acute exacerbation 
295.55 Latent schizophrenia, in remission 
295.60 Schizophrenic disorders, residual type, unspecified 
295.61 Schizophrenic disorders, residual type, subchronic 
295.62 Schizophrenic disorders, residual type, chronic 
295.63 Schizophrenic disorders, residual type, subchronic with acute exacerbation 
295.64 Schizophrenic disorders, residual type, chronic with acute exacerbation 
295.65 Schizophrenic disorders, residual type, in remission 
295.70 Schizoaffective disorder, unspecified 
295.71 Schizoaffective disorder, subchronic 
295.72 Schizoaffective disorder, chronic 
295.73 Schizoaffective disorder, subchronic with acute exacerbation 
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295.74 Schizoaffective disorder, chronic with acute exacerbation 
295.75 Schizoaffective disorder, in remission 
295.80 Other specified types of schizophrenia, unspecified 
295.81 Other specified types of schizophrenia, subchronic 
295.82 Other specified types of schizophrenia, chronic 
295.83 Other specified types of schizophrenia, subchronic with acute exacerbation 
295.84 Other specified types of schizophrenia, chronic with acute exacerbation 
295.85 Other specified types of schizophrenia, in remission 
295.90 Unspecified schizophrenia, unspecified 
295.91 Unspecified schizophrenia, subchronic 
295.92 Unspecified schizophrenia, chronic 
295.93 Unspecified schizophrenia, subchronic with acute exacerbation 
295.94 Unspecified schizophrenia, chronic with acute exacerbation 
295.95 Unspecified schizophrenia, in remission 
297.0 Paranoid state, simple  
297.1 Delusional disorder  
297.2 Paraphrenia  
297.3 Shared psychotic disorder  
297.8 Other specified paranoid states  
297.9 Unspecified paranoid state  
298.0 Depressive type psychosis  
298.1 Excitative type psychosis  
298.2 Reactive confusion  
298.3 Acute paranoid reaction  
298.4 Psychogenic paranoid psychosis  
298.8 Other and unspecified reactive psychosis  
298.9 Unspecified psychosis  
F20.0 Paranoid schizophrenia  
F20.1 Disorganized schizophrenia  
F20.2 Catatonic schizophrenia 
F20.3 Undifferentiated schizophrenia  
F20.5 Residual schizophrenia  
F20.81 Schizophreniform disorder 
F20.89 Other schizophrenia 
F20.9 Schizophrenia, unspecified  
F21 Schizotypal disorder 
F22 Delusional disorders 
F23 Brief psychotic disorder 
F24 Shared psychotic disorder 
F25.0 Schizoaffective disorder, bipolar type  
F25.1 Schizoaffective disorder, depressive type  
F25.8 Other schizoaffective disorders  
F25.9 Schizoaffective disorder, unspecified  
F28 Other psychotic disorder not due to a substance or known physiological condition 
F29 Unspecified psychosis not due to a substance or known physiological condition 
Anxiety Disorders 
300.00 Anxiety state, unspecified 
300.01 Panic disorder without agoraphobia 
300.02 Generalized anxiety disorder 
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300.09 Other anxiety states 
300.10 Hysteria, unspecified 
300.11 Conversion disorder 
300.12 Dissociative amnesia 
300.13 Dissociative fugue 
300.14 Dissociative identity disorder 
300.15 Dissociative disorder or reaction, unspecified 
300.16 Factitious disorder with predominantly psychological signs and symptoms 
300.19 Other and unspecified factitious illness 
300.20 Phobia, unspecified 
300.21 Agoraphobia with panic disorder 
300.22 Agoraphobia without mention of panic attacks 
300.23 Social phobia 
300.29 Other isolated or specific phobias 
F40.00 Agoraphobia, unspecified 
F40.01 Agoraphobia with panic disorder 
F40.02 Agoraphobia without panic disorder 
F40.10 Social phobia, unspecified 
F40.11 Social phobia, generalized 
F40.210 Arachnophobia  
F40.218 Other animal type phobia  
F40.220 Fear of thunderstorms  
F40.228 Other natural environment type phobia  
F40.230 Fear of blood  
F40.231 Fear of injections and transfusions  
F40.232 Fear of other medical care  
F40.233 Fear of injury  
F40.240 Claustrophobia  
F40.241 Acrophobia  
F40.242 Fear of bridges  
F40.243 Fear of flying  
F40.248 Other situational type phobia  
F40.290 Androphobia  
F40.291 Gynephobia  
F40.298 Other specified phobia 
F40.8 Other phobic anxiety disorders  
F40.9 Phobic anxiety disorder, unspecified  
F41.0 Panic disorder [episodic paroxysmal anxiety] without agoraphobia  
F41.1 Generalized anxiety disorder  
F41.3 Other mixed anxiety disorders  
F41.8 Other specified anxiety disorders  
F41.9 Anxiety disorder, unspecified  
Personality Disorders 
301.0 Paranoid personality disorder  
301.10 Affective personality disorder, unspecified 
301.11 Chronic hypomanic personality disorder 
301.12 Chronic depressive personality disorder 
301.13 Cyclothymic disorder 
301.20 Schizoid personality disorder, unspecified 
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301.21 Introverted personality 
301.22 Schizotypal personality disorder 
301.3 Explosive personality disorder  
301.4 Obsessive-compulsive personality disorder  
301.50 Histrionic personality disorder, unspecified 
301.51 Chronic factitious illness with physical symptoms 
301.59 Other histrionic personality disorder 
301.6 Dependent personality disorder  
301.7 Antisocial personality disorder  
301.81 Narcissistic personality disorder 
301.82 Avoidant personality disorder 
301.83 Borderline personality disorder 
301.84 Passive-aggressive personality  
301.89 Other personality disorders 
301.9 Unspecified personality disorder 
F60.0 Paranoid personality disorder  
F60.1 Schizoid personality disorder  
F60.2 Antisocial personality disorder  
F60.3 Borderline personality disorder  
F60.4 Histrionic personality disorder  
F60.5 Obsessive-compulsive personality disorder  
F60.6 Avoidant personality disorder  
F60.7 Dependent personality disorder  
F60.81 Narcissistic personality disorder 
F60.89 Other specific personality disorders 
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